B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 71 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2014', provides an overview of the B-Cell Chronic Lymphocytic Leukemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for B-Cell Chronic Lymphocytic Leukemia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the B-Cell Chronic Lymphocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the B-Cell Chronic Lymphocytic Leukemia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
B-Cell Chronic Lymphocytic Leukemia Overview 8
Therapeutics Development 9
Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Overview 9
Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis 10
B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Development by Companies 11
B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Investigation by Universities/Institutes 12
B-Cell Chronic Lymphocytic Leukemia - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
B-Cell Chronic Lymphocytic Leukemia - Products under Development by Companies 15
B-Cell Chronic Lymphocytic Leukemia - Products under Investigation by Universities/Institutes 16
B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development 17
AbbVie Inc. 17
Amgen Inc. 18
BioNovion B.V. 19
Cognosci, Inc. 20
Immunomedics, Inc. 21
MABLife S.A.S 22
Nippon Shinyaku Co., Ltd. 23
Ono Pharmaceutical Co., Ltd. 24
SBI Biotech Co., Ltd. 25
TheraMAB LLC. 26
Vivia Biotech, S.L. 27
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
202-b - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
alemtuzumab biosimilar - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
AMG-319 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
bafetinib - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Cell Therapy for B-Cell Chronic Lymphocytic Leukemia - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Cell Therapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Cell Therapy to Target CD19 for Cancer - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Cell Therapy to Target CD19 for Oncology - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
COG-112 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
GNKG-168 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GNKS-356 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
IDD-001 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
IDD-002 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ilorasertib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
MAT-304 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Monoclonal Antibody to Inhibit APRIL for B-Cell Chronic Lymphocytic Leukemia and Multiple Myeloma - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ONO-4059 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Small Molecules for Oncology - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
TAB-08 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Vivia-009 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
B-Cell Chronic Lymphocytic Leukemia - Recent Pipeline Updates 64
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects 66
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products 67
B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones 68
Featured News & Press Releases 68
Dec 12, 2011: CytRx Announces Presentation Of Favorable Phase II Results With Bafetinib In Relapsed B-Cell Chronic Lymphocytic Leukemia At ASH Conference 68
Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia 69
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 71
Disclaimer 71

List of Tables
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2014 9
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
B-Cell Chronic Lymphocytic Leukemia - Pipeline by AbbVie Inc., H2 2014 17
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Amgen Inc., H2 2014 18
B-Cell Chronic Lymphocytic Leukemia - Pipeline by BioNovion B.V., H2 2014 19
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Cognosci, Inc., H2 2014 20
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics, Inc., H2 2014 21
B-Cell Chronic Lymphocytic Leukemia - Pipeline by MABLife S.A.S, H2 2014 22
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Nippon Shinyaku Co., Ltd., H2 2014 23
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 24
B-Cell Chronic Lymphocytic Leukemia - Pipeline by SBI Biotech Co., Ltd., H2 2014 25
B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC., H2 2014 26
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Vivia Biotech, S.L., H2 2014 27
Assessment by Monotherapy Products, H2 2014 28
Number of Products by Stage and Target, H2 2014 30
Number of Products by Stage and Mechanism of Action, H2 2014 32
Number of Products by Stage and Route of Administration, H2 2014 34
Number of Products by Stage and Molecule Type, H2 2014 36
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Recent Pipeline Updates, H2 2014 64
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H2 2014 66
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H2 2014 67